• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于人群的建模方法与基于队列的建模方法。

Population- versus cohort-based modelling approaches.

机构信息

Department of Public Health Sciences, University of Lige, Lige, Belgium.

出版信息

Pharmacoeconomics. 2012 Mar;30(3):171-81. doi: 10.2165/11593050-000000000-00000.

DOI:10.2165/11593050-000000000-00000
PMID:22283692
Abstract

While no single type of model can provide adequate answers under all circumstances, any modelling endeavour should incorporate three fundamental considerations in any decision-making question: the target population, the disease and the intervention characteristics. A target population is likely to be characterized by various types of heterogeneity and a dynamic evolution over time. It is therefore important to adequately capture these population effects on the results of a model. There are essentially two different approaches in modelling a population over time: a cohort-based approach and a population-based approach. In a cohort-based model, a closed group of individuals who have at least one specific characteristic or experience in common over a defined period of time is run through a state transition process. The cohort is generally composed of a hypothetical number of representative or 'average' individuals (i.e. the target population is considered to be a homogeneous group). The population-based approach projects the evolution of the estimated prevalent target population and intends to reflect as much as possible the demographic, epidemiological and clinical characteristics of the prevalent target population relevant for the decision problem. A cohort-based approach is generally used in most published healthcare decision models. However, this choice is rarely discussed by modellers. In this article, we challenge this assumption. To address the underlying decision problem, we affirm it is crucial that modellers consider the characteristics of the target population. Then, they could opt for using the most appropriate approach. Decision makers should also understand the impact on the results of both types of models in order to make informed healthcare decisions.

摘要

虽然没有任何一种模型可以在所有情况下提供充分的答案,但任何建模工作都应该在任何决策问题中纳入三个基本考虑因素:目标人群、疾病和干预措施的特征。目标人群可能具有各种类型的异质性,并随着时间的推移发生动态演变。因此,重要的是要充分捕捉这些人群效应对模型结果的影响。基本上有两种不同的方法可以随时间对人群进行建模:基于队列的方法和基于人群的方法。在基于队列的模型中,通过状态转移过程来运行一个具有至少一个特定特征或共同经历的封闭人群。该队列通常由具有代表性或“平均”个体的假设数量组成(即目标人群被认为是同质群体)。基于人群的方法则预测估计的现有目标人群的演变,并尽可能反映与决策问题相关的现有目标人群的人口统计学、流行病学和临床特征。基于队列的方法通常用于大多数已发表的医疗保健决策模型中。然而,建模者很少讨论这种选择。在本文中,我们对这一假设提出质疑。为了解决潜在的决策问题,我们肯定建模者考虑目标人群的特征至关重要。然后,他们可以选择使用最合适的方法。决策者还应该了解这两种模型对结果的影响,以便做出明智的医疗保健决策。

相似文献

1
Population- versus cohort-based modelling approaches.基于人群的建模方法与基于队列的建模方法。
Pharmacoeconomics. 2012 Mar;30(3):171-81. doi: 10.2165/11593050-000000000-00000.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
4
A review and critique of modelling in prioritising and designing screening programmes.对筛查项目的优先级确定与设计中建模方法的综述与批判
Health Technol Assess. 2007 Dec;11(52):iii-iv, ix-xi, 1-145. doi: 10.3310/hta11520.
5
Risk management frameworks for human health and environmental risks.人类健康与环境风险的风险管理框架。
J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. doi: 10.1080/10937400390208608.
6
Generalisability in economic evaluation studies in healthcare: a review and case studies.医疗保健经济评估研究中的可推广性:综述与案例研究
Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. doi: 10.3310/hta8490.
7
A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.对所有医疗环境中共同决策的内部和外部影响进行的定性系统评价。
JBI Libr Syst Rev. 2012;10(58):4633-4646. doi: 10.11124/jbisrir-2012-432.
8
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.基于组织学的癌症药物建模方法,为 NICE 评估提供信息:系统评价和决策框架。
Health Technol Assess. 2021 Dec;25(76):1-228. doi: 10.3310/hta25760.
9
The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.综合护理路径在医疗环境中对成人和儿童的有效性:一项系统评价。
JBI Libr Syst Rev. 2009;7(3):80-129. doi: 10.11124/01938924-200907030-00001.
10
Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD).通过应用显示省略对象的决策分析模型(DAMWOOD)来提高决策模型的透明度。
Pharmacoeconomics. 2024 Nov;42(11):1197-1208. doi: 10.1007/s40273-024-01401-y. Epub 2024 Aug 7.

引用本文的文献

1
Predictive Ability of Previous Pain and Disease Conditions on the Presentation of Post-COVID Pain in a Danish Cohort of Adult COVID-19 Survivors.丹麦成年新冠病毒病幸存者队列中既往疼痛和疾病状况对新冠后疼痛表现的预测能力
Eur J Pain. 2025 May;29(5):e70021. doi: 10.1002/ejp.70021.
2
Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant.在比利时奥密克戎变异株背景下,奈玛特韦-利托那韦作为治疗新冠病毒感染的真实世界成本效益分析
Front Public Health. 2025 Feb 3;12:1432821. doi: 10.3389/fpubh.2024.1432821. eCollection 2024.
3
Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness.

本文引用的文献

1
Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis.在成本效益分析中考虑药物生命周期和未来药物价格。
Pharmacoeconomics. 2011 Jan;29(1):1-15. doi: 10.2165/11584230-000000000-00000.
2
Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?疫苗偶联物在肺炎球菌疾病中的效果建模:队列模型还是人群模型?
Vaccine. 2010 Nov 19;28 Suppl 6:G30-8. doi: 10.1016/j.vaccine.2010.06.015.
3
Appropriate cohorts for cost-effectiveness analysis: to mix or not to mix?成本效益分析的合适队列:混合还是不混合?
根据世界卫生组织目标消除丙型肝炎的自我检测策略:疾病负担与成本效益分析
Clin Mol Hepatol. 2025 Jan;31(1):166-178. doi: 10.3350/cmh.2024.0484. Epub 2024 Oct 4.
4
Cost-effectiveness analysis of insecticide ban aimed at preventing Parkinson's disease in Central California.加利福尼亚州中部杀虫剂禁令预防帕金森病的成本效益分析。
Sci Total Environ. 2024 Feb 20;912:168913. doi: 10.1016/j.scitotenv.2023.168913. Epub 2023 Nov 30.
5
The long-term impact and value of curative therapy for HIV: a modelling analysis.长效治疗对 HIV 的长期影响和价值:建模分析。
J Int AIDS Soc. 2023 Sep;26(9):e26170. doi: 10.1002/jia2.26170.
6
Modeling the public health impact of voxelotor in the management of sickle cell disease in France.建立数学模型评估法国用 voxolotor 治疗镰状细胞病的公共卫生影响
PLoS One. 2023 Sep 13;18(9):e0291211. doi: 10.1371/journal.pone.0291211. eCollection 2023.
7
The Economic Value of Rotavirus Vaccination When Optimally Implemented in a High-Income Country.在高收入国家最佳实施轮状病毒疫苗接种的经济价值。
Vaccines (Basel). 2023 Apr 28;11(5):917. doi: 10.3390/vaccines11050917.
8
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.依洛尤单抗的成本效益、疾病负担和预算影响:心血管疾病真实世界人群的动态队列模型。
Pharmacoeconomics. 2022 Aug;40(8):791-806. doi: 10.1007/s40273-022-01152-8. Epub 2022 Jun 20.
9
Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.评估德国成人序贯肺炎球菌疫苗接种计划的成本效益。
PLoS One. 2018 May 24;13(5):e0197905. doi: 10.1371/journal.pone.0197905. eCollection 2018.
10
3. How comprehensive can we be in the economic assessment of vaccines?3. 在疫苗的经济评估中,我们能做到多全面?
J Mark Access Health Policy. 2017 Aug 31;5(1):1336044. doi: 10.1080/20016689.2017.1336044. eCollection 2017.
Med Decis Making. 2010 Jul-Aug;30(4):424-5. doi: 10.1177/0272989X10375038.
4
Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.谁的成本和收益?为什么经济评估应该模拟现患和所有未来新发患者队列。
Med Decis Making. 2010 Jul-Aug;30(4):426-37. doi: 10.1177/0272989X09353946. Epub 2010 Mar 12.
5
Budget impact analysis: review of the state of the art.预算影响分析:技术现状综述。
Expert Rev Pharmacoecon Outcomes Res. 2005 Feb;5(1):65-79. doi: 10.1586/14737167.5.1.65.
6
Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.开发和验证用于骨质疏松症治疗经济评估的马尔可夫微模拟模型。
Value Health. 2009 Jul-Aug;12(5):687-96. doi: 10.1111/j.1524-4733.2008.00497.x.
7
Comparison of Markov model and discrete-event simulation techniques for HIV.用于艾滋病病毒的马尔可夫模型与离散事件模拟技术的比较。
Pharmacoeconomics. 2009;27(2):159-65. doi: 10.2165/00019053-200927020-00006.
8
Subgroups and heterogeneity in cost-effectiveness analysis.成本效益分析中的亚组与异质性
Pharmacoeconomics. 2008;26(9):799-806. doi: 10.2165/00019053-200826090-00009.
9
Modelling approaches: the case of schizophrenia.建模方法:精神分裂症的案例
Pharmacoeconomics. 2008;26(8):633-48. doi: 10.2165/00019053-200826080-00002.
10
A new tool for epidemiology: the usefulness of dynamic-agent models in understanding place effects on health.流行病学的一种新工具:动态主体模型在理解地域对健康的影响方面的作用。
Am J Epidemiol. 2008 Jul 1;168(1):1-8. doi: 10.1093/aje/kwn118. Epub 2008 May 13.